title: Changes in background electroencephalography and regional cerebral glucose metabolism in focal epilepsy patients after 1-month administration of levetiracetam.
abstract: The antiseizure efficacy and safety of levetiracetam (LEV) is well documented; however, few clinical studies have investigated the predictability of patient responsiveness to LEV, especially when the drug is first administered. The aim of this study was to ascertain the utility of clinical, electrophysiological, and neuroimaging parameters for assessing the early response to LEV treatment in focal epilepsy patients. Twelve confirmed focal epilepsy patients were included who had never taken LEV before. At baseline and 1 month after LEV administration, all subjects underwent 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and electroencephalography (EEG), and completed the Quality of Life in Epilepsy questionnaire (QOLIE-31). Participants were divided by drug response: good versus poor. The good response group (seven subjects) was defined by a >50% decrease in seizure frequency compared to baseline (3 months before LEV intake). The other five participants with a <50% decrease in seizure frequency were placed into the poor response group. We compared the differential changes in brain glucose metabolism on FDG-PET, power spectrum on the EEG, and QOLIE-31 results between the two groups after a 1-month LEV trial. In the good response group, it was possible to identify brain regions with increased glucose metabolism, including the bilateral caudate nuclei and both frontal and left parietal regions (uncorrected P<0.005). In the poor response group, FDG-PET did not reveal any areas with significantly increased glucose metabolism. In the good response group, spectral EEG analysis revealed decreased delta power (1-3 Hz, P<0.05) in the parietal region and increased beta1 power (13-19 Hz, P<0.05) in the frontal region, whereas no significant changes were observed in the poor response group. There were no significant changes on the QOLIE-31 in either group after a 1-month LEV trial. Our results suggest that LEV-induced glucose metabolism and EEG spectral changes may be indicative of initial drug responsiveness as early as 1 month following treatment initiation. These parameters may be useful prognostic markers of antiseizure effects caused by LEV medication or may indicate an epiphenomenon of LEV-induced changes in glucose metabolism and EEG frequency. Further studies with larger sample sizes are warranted.
authors: Department of Neurology, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea.
authors: Seong Hoon
authors: SH
authors: Kim
authors: Department of Neurology, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea ; Catholic Neuroscience Institute, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea.
authors: Sung-Chul
authors: SC
authors: Lim
authors: Department of Neurology, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea ; Catholic Neuroscience Institute, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea.
authors: Woojun
authors: W
authors: Kim
authors: Department of Biomedical Engineering, Hanyang University, Seoul, Republic of Korea.
authors: Oh-Hun
authors: OH
authors: Kwon
authors: Department of Biomedical Engineering, Hanyang University, Seoul, Republic of Korea.
authors: Chan Mi
authors: CM
authors: Kim
authors: Department of Biomedical Engineering, Hanyang University, Seoul, Republic of Korea.
authors: Jong-Min
authors: JM
authors: Lee
authors: Department of Neurology, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea ; Catholic Neuroscience Institute, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea.
authors: Young-Min
authors: YM
authors: Shon
keywords: FDG-PET; background EEG; power spectral change; responsiveness
references: Neuroimage. 2007 Feb 15;34(4):1600-11
references: 17207640
references: Front Neurol. 2013 Dec 04;4:192
references: 24363651
references: Ann Neurol. 1989 May;25(5):516-20
references: 2774494
references: Neurosci Lett. 2005 Jun 24;381(3):309-13
references: 15896490
references: Seizure. 2013 Jul;22(6):416-23
references: 23628168
references: Clin Neuropharmacol. 1999 Mar-Apr;22(2):80-6
references: 10202602
references: Arch Neurol. 1994 Feb;51(2):139-44
references: 8304838
references: Clin Neurophysiol. 2012 May;123(5):883-91
references: 22000706
references: Int J Psychophysiol. 1994 Oct;18(1):49-65
references: 7876038
references: Clin Neuropharmacol. 2001 Sep-Oct;24(5):284-9
references: 11586113
references: Epilepsy Behav. 2004 Feb;5 Suppl 1:S60-5
references: 14725848
references: Epilepsia. 2006 Apr;47(4):695-703
references: 16650135
references: Epilepsia. 1997 Apr;38(4):430-8
references: 9118848
references: Epilepsia. 1991 May-Jun;32(3):417-22
references: 2044503
references: Neuropsychol Rev. 2007 Dec;17(4):413-25
references: 17943448
references: J Clin Neurol. 2011 Sep;7(3):128-36
references: 22087206
references: Epilepsia. 1998 Jan;39(1):81-8
references: 9578017
references: Arch Neurol. 2006 Sep;63(9):1282-6
references: 16966506
references: Hum Brain Mapp. 2002 Jan;15(1):1-25
references: 11747097
references: J Clin Neurol. 2009 Dec;5(4):178-85
references: 20076799
references: Epilepsia. 2002 May;43(5):482-90
references: 12027908
references: Epilepsia. 1989 Sep-Oct;30(5):590-6
references: 2507304
references: Hum Brain Mapp. 2000 Jul;10(3):120-31
references: 10912591
references: J Clin Neurol. 2008 Sep;4(3):99-106
references: 19513311
references: Epilepsy Behav. 2008 Nov;13(4):642-9
references: 18707022
references: Philos Trans R Soc Lond B Biol Sci. 2001 Aug 29;356(1412):1293-322
references: 11545704
references: Methods Find Exp Clin Pharmacol. 2002;24 Suppl D:5-12
references: 12575463
references: Electroencephalogr Clin Neurophysiol. 1992 Jul;83(1):19-23
references: 1376662
references: Clin Neuropharmacol. 1998 Jan-Feb;21(1):41-7
references: 9579284